ABSTRACT
Introduction During the COVID-19 pandemic, the shortage of personal protective equipment (PPE) was well-reported and discussed, not only in the healthcare sector but across all of society as the demands for PPE skyrocketed. As hospitalizations for COVID-19-related illness continue to increase, many recent reports indicate the supply of PPE is persistently and significantly less than the demand. These PPE shortages encouraged communities of 3D printing experts and hobbyists to design and distribute homemade, 3D-printed PPE, including N95 mask substitutes. The mask presented, the Kansas City Mask (KC Mask), is one such product which was created from the maker community in partnership with local physicians and hospitals. This report discusses the design, manufacturing, and validation of the KC Mask design and its usage in the COVID-19 pandemic as well as future use as stopgap PPE.
Methods The KC Mask was adapted from a similar design called the Montana Mask. Mask components were 3D printed and assembled then fit tested by qualitative fit testing (QLFT) at Truman Medical Center in Kansas City, MO as a proof of concept.
Results The QLFT was successful and the KC Mask was approved for use by pandemic response administration staff at the hospital. Fortunately, the KC Mask has not required wide utilization, however, because supply chains for Kansas City area hospitals have, at the time of this publication, not yet been exhausted by the pandemic.
Conclusion The results of Truman Medical Center’s approval of the KC Mask are promising for this N95 stop-gap substitute. Although further analysis and study is needed for this design, persistently increasing caseloads and PPE shortages necessitate an urgent dissemination of these preliminary results. The authors do not advocate for the KC Mask as a replacement of traditional N95 masks or other PPE but do endorse the KC Mask as a stopgap measure, proven to be effective in situations of dire PPE shortage based on CDC guidelines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding provided.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval was not requested nor required for this study because this was a proof of concept and quality improvement initiative.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The sources for all data referenced in this manuscript can be found in the references section of the manuscript.
